Key Takeaways

• GSK spun off its consumer healthcare business as Haleon, becoming a more focused biopharmaceutical company centred on vaccines, specialty medicine and general medicine.

• Vaccines, including its RSV vaccine Arexvy, and its majority-owned HIV specialist ViiV Healthcare, are key growth pillars for the group.

• Patent expiries on older medicines are a recurring theme in pharma, making pipeline delivery and new product launches central to sustaining growth.

• Historic Zantac litigation has been a significant overhang on sentiment, with resolution progress closely tracked by the market.

• Research and development investment intensity is a defining characteristic of the pharmaceutical sector, with mixed clinical trial outcomes an inherent risk.

Company Overview

GSK plc is a major global biopharmaceutical company focused on vaccines, specialty medicines and general medicines, following the demerger of its consumer healthcare division as the separately listed Haleon. The company holds a majority stake in ViiV Healthcare, a business dedicated specifically to HIV treatment and prevention that has become one of GSK's most valuable assets.

Refocusing on biopharma has been positioned by management as a way to concentrate capital and research investment on higher-margin, innovation-driven areas of medicine rather than spreading resources across pharma, vaccines and consumer products simultaneously.

Vaccines and the ViiV HIV Franchise

GSK's vaccines portfolio, including its respiratory syncytial virus (RSV) vaccine Arexvy alongside established shingles and other immunisation products, is a core growth pillar, particularly as ageing populations in developed markets increase demand for vaccination against respiratory illnesses.

ViiV Healthcare's HIV treatment and long-acting prevention therapies represent another significant and highly profitable franchise, with continued innovation in long-acting injectable treatments seen as a differentiator versus daily oral regimens.

Pipeline and Patent Cliff Management

Like all major pharmaceutical companies, GSK faces the ongoing challenge of patent expiries on established medicines, which open the door to generic competition and can erode revenue from previously reliable products. Sustaining growth requires a steady flow of new approvals and successful late-stage clinical trials across oncology, respiratory and other specialty areas to offset this natural attrition.

The Zantac Litigation Overhang

Legacy litigation related to the discontinued heartburn medicine Zantac, alleging links to cancer, weighed heavily on sentiment for an extended period as the company worked through settlements in various jurisdictions. Progress, or setbacks, in resolving remaining claims continues to be a factor some investors track closely alongside the underlying pharmaceutical business performance.

Dividend and Valuation Considerations

GSK has maintained a dividend as part of its investment case, with the level tied to underlying earnings and the balance between funding research investment, litigation costs and shareholder returns. Valuation discussions in pharma typically weigh pipeline value and patent cliff exposure alongside near-term earnings multiples.

Investor Sentiment

Sentiment toward GSK has improved as clarity around litigation exposure has increased and as the vaccines and specialty medicine pipeline has shown signs of delivering, though the stock remains sensitive to individual clinical trial readouts and regulatory decisions, as is typical across the pharmaceutical sector.

Key Risks to Watch

• Patent expiries on established medicines create ongoing pressure to replace lost revenue with new products.

• Clinical trial outcomes are inherently uncertain, and setbacks can materially affect pipeline value.

• Legacy litigation, including Zantac-related claims, carries residual financial and reputational risk.

• Drug pricing policy and regulatory decisions in major markets, particularly the US, can affect commercial returns.

• Currency movements affect a company with substantial international revenue exposure.